Quantcast
Last updated on April 18, 2014 at 9:36 EDT

Latest Collegium Pharmaceutical Inc. Stories

2013-05-31 08:24:38

CANTON, Mass., May 31, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the Company's President and CEO, Michael Heffernan, will present the Company's corporate overview on Tuesday, June 4, 2013 at 3:00pm EDT at the Jefferies 2013 Global Health Care Conference. The conference will be held at the Grand Hyatt New York in New York City. The Company's lead development program is Oxycodone DETERx(®), an abuse-deterrent,...

2013-05-17 08:23:06

CANTON, Mass., May 17, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the Company's President and CEO, Michael Heffernan, will present the Company's corporate overview on Monday, May 20, 2013 at 1:30pm EDT at the UBS Global Health Care Conference. The conference will be held at the Sheraton New York Hotel in New York City. The Company's lead development program is Oxycodone DETERx(®), an abuse-deterrent, extended-release...

2013-05-08 08:30:13

CANTON, Mass., May 8, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the presentation of a scientific poster titled "Oxycodone DETERx®, an Extended-release, Abuse-deterrent Formulation for the Management of Chronic Pain," at the American Pain Society's 32(nd) Annual Scientific Meeting, held in New Orleans, Louisiana from May 8(th) to May 10(th). This...

2013-04-30 08:33:20

Over 1,000 chronic pain patients currently on opioids surveyed to understand and quantify the potential market opportunity for Collegium's DETERx® based product candidates CANTON, Mass., April 30, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the completion of a 1,021 patient survey, which consisted of patients with chronic pain currently on opioid...

2013-04-22 08:28:27

11 million people in the U.S. estimated to be suffering from chronic pain and dysphagia CANTON, Mass., April 22, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the completion of a research study, conducted with an independent market research firm, that identified a significant unmet medical need for improved treatments for patients with chronic pain and...

2013-04-17 08:28:55

-Oxycodone DETERx® resistant to tampering via chewing and crushing CANTON, Mass., April 17, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced top-line results from its recently completed Phase I clinical trial for Oxycodone DETERx®, its extended-release, abuse-deterrent, multi-particulate product in a capsule form. The product utilizes Collegium's...

2013-04-03 08:27:27

Company to explore commercial partnerships for its lead product, Oxycodone DETERx® (COL-003), an abuse-deterrent, extended-release product for chronic pain CANTON, Mass., April 3, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, has hired Douglas Carlson in the newly-created position of Vice President of Business Development. Doug previously held the position of Senior...

2013-02-28 08:29:03

CANTON, Mass., Feb. 28, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the company's President and CEO, Michael Heffernan, will present the company's corporate overview on Wednesday, March 6, 2013 at 11:00 am EST at the Cowen & Company 33(rd) Annual Health Care Conference. The conference will be held at the Boston Marriott Copley Place in Boston, Massachusetts. The Company's lead development program is Oxycodone...

2013-02-12 08:29:25

CANTON, Mass., Feb. 12, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has received Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Abuse-Deterrent Drug Formulation" US Patent Application Number 12/823,628. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued. This...

2013-01-17 08:25:58

CANTON, Mass., Jan. 17, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the relocation of its corporate offices and laboratory facilities to Canton, Massachusetts from Cumberland, Rhode Island. The Company's lead development program is Oxycodone DETERx(®) (COL-003), a tamper-resistant, extended-release oxycodone product utilizing its proprietary DETERx(®...